Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Subscribe To Our Newsletter & Stay Updated
